StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30243% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Zepatier (elbasvir and grazoprevir by Quarter

Zepatier (elbasvir and grazoprevir — HCV, legacy) — International sales ($M) ($M)

QuarterlyAnnual

Merck Zepatier (elbasvir and grazoprevir: $24M in Q4 2020, down 45.5% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2020
24
Period ended Dec 31, 2020
Change on a year earlier
-45.5%
44 in Q4 2019
History
17 quarters
Since Q4 2016
Sources
11
Documents cited below

Where the Q4 2020 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2021-02-25) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZepatier (elbasvir and grazoprevir — HCV, legacy) — International sales ($M) ($M)Year on yearSource
Q4 2020Dec 31, 202024-45.5%Form 10-K (filed 2021-02-25) ↗
Q3 2020Sep 30, 202022-62.7%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 202024-64.7%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 202037-54.3%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2019Dec 31, 201944-59.3%Form 10-K (filed 2021-02-25) ↗
Q3 2019Sep 30, 201959-31.4%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2019Jun 30, 201968-44.7%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2019Mar 31, 201981-38.2%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2018Dec 31, 2018108-48.1%Form 10-K (filed 2021-02-25) ↗
Q3 2018Sep 30, 201886-64.3%Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2018Jun 30, 2018123-52.9%Form 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q1 2018Mar 31, 2018131-26.4%Form 10-Q (filed 2019-05-08) ↗
Q4 2017Dec 31, 2017208+324.5%Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗
Q3 2017Sep 30, 2017241–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2017Jun 30, 2017261–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗
Q1 2017Mar 31, 2017178–Form 10-Q (filed 2018-05-08) ↗

Breakdown

What makes up zepatier (elbasvir and grazoprevir

Cite this data

StockData. (2026). Merck Zepatier (elbasvir and grazoprevir ($M), quarterly Q4 2016–Q4 2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zepatier-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.

See a number that looks wrong?